Floatz logo

Olaparib

BRCA Mutation

Okayama UniversitySmall moleculePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the BRCA Mutation cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
European Institute of Oncology
Phase 2CCC
Pembrolizumab
Okayama University
Phase 2CCC
Cyclophosphamide
Okayama University
Phase 2CCC
Tranexamic Acid
Northwestern University
Phase 2CCC
Epirubicin
Okayama University
Phase 2CCC

View all 12 →

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →